The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study
Journal of Gastroenterology and Hepatology · 2024-04 · 39 (4) · 658-666
DOI: 10.1111/jgh.16471 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 22.01.2024. Verfasst von Qianjun Zhuang und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Amines, Esophagitis, Peptic, Gastroesophageal Reflux, Peptic Ulcer. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Daewoong Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Company.
Abstract (Originalsprache)
Background and Aim Fexuprazan is a novel potassium‐competitive acid blocker (P‐CAB). This study aimed to explore the noninferior efficacy and safety of fexuprazan to esomeprazole in treating erosive esophagitis (EE).
Methods
This was a phase III, randomized, double‐blind multicenter study. Patients with endoscopically confirmed EE were randomized to receive fexuprazan 40 mg or esomeprazole 40 mg once a daily for 4–8 weeks. The healing rates of EE, symptom response, GERD‐health‐related quality life (GERD‐HRQL), and treatment‐emergent adverse events (TEAEs) were compared between fexuprazan group and esomeprazole group.
Results
A total of 332 subjects were included in full analysis set (FAS) and 311 in per‐protocol set (PPS). The healing rates of fexuprazan and esomeprazole groups at 8 weeks were 88.5% (146/165) and 89.0% (145/163), respectively, in FAS and 97.3% (145/149) and 97.9% (143/146), respectively, in PPS. Noninferiority of fexuprazan compared with esomeprazole according to EE healing rates at 8 weeks was demonstrated in both FAS and PPS analysis. No significant difference was found between groups in EE healing rates at 4 weeks, symptom responses, and changes of GERD‐HRQL. The incidence of drug‐related AEs was 19.4% (32/165) in fexuprazan arm and 19.6% (32/163) in esomeprazole arm.
Conclusion
This study demonstrated noninferior efficacy of fexuprazan to esomeprazole in treating EE. The incidence of TEAEs was similar between fexuprazan and esomeprazole. Trial registration number NCT05813561.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Gastroenterology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
- Department of Gastroenterology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
- Department of Gastroenterology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Gastroenterology, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
ORCID-Profile: Yongjian Zhou, Yanqing Li, Yinglian Xiao
Förderung
- Daewoong Pharmaceutical Co., Ltd.
- Daewoong Pharmaceutical Company
Zitieren
APA
Zhuang, Q., Liao, A., He, Q., Liu, C., Zheng, C., Li, X., Liu, Y., Wang, B., Liu, S., Zhang, Y., Lin, R., Chen, H., Deng, M., Tang, Y., He, C., Dai, W., Tang, H., Gong, L., Li, L., …, & Xiao, Y. (2024). The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study. Journal of Gastroenterology and Hepatology, 39(4), 658-666. https://doi.org/10.1111/jgh.16471
Vancouver
Zhuang Q, Liao A, He Q, Liu C, Zheng C, Li X, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study. Journal of Gastroenterology and Hepatology. 2024;39(4):658-666. doi:10.1111/jgh.16471
BibTeX
@article{Zhuang2024,
author = {Zhuang, Qianjun and Liao, Aijun and He, Qingling and Liu, Chengxia and Zheng, Changqing and Li, Xing and Liu, Youli and Wang, Bangmao and Liu, Side and Zhang, Yan and Lin, Rong and Chen, Huixin and Deng, Min and Tang, Yanping and He, Chiyi and Dai, Weijie and Tang, Haitao and Gong, Lei and Li, Liangping and Xu, Baohong and Yang, Changqing and Zhou, Bingxi and Su, Dongxing and Guo, Qinghong and Li, Bin and Zhou, Yongjian and Wang, Xiaoyang and Fei, Sujuan and Wu, Huili and Wei, Sichen and Peng, Zhihong and Wang, Jianning and Li, Yanqing and Wang, Hong and Deng, Tianwei and Ding, Shigang and Li, Fangfang and Chen, Minhu and Xiao, Yinglian},
title = {The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
volume = {39},
number = {4},
pages = {658--666},
doi = {10.1111/jgh.16471}
}
EUVIMED